linsitinib

Term ID

CHEBI:91402

Synonyms

ASP-7487
cis-3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol
cis-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol
linsitinib
linsitinibum
OSI 906
OSI 906AA
OSI-906
OSI-906AA
OSI906

Definition

An imidazopyrazine that is imidazo[1,5-a]pyrazine substituted by 2-phenylquinolin-7-yl, cis-3-hydroxy-3-methylcyclobutyl, and amino groups at positions 1, 3, and 8, respectively. It is dual inhibitor of the IGF-1 receptor and insulin receptor (IC₅₀ = 35 and 75 nM, respectively) that was previously in clinical development for the treatment of cancer and thyroid eye disease.

References

cas:867160-71-2
drugbank:DB06075
hmdb:HMDB0254107
kegg.drug:D09925
lincs.smallmolecule:LSM-1135
patent:EP2427192
patent:WO2011163430
pmc:PMC10555290
pubmed:20530704
pubmed:24726739
pubmed:25335932
pubmed:25795408
pubmed:26831715
pubmed:27686971
pubmed:27694157
pubmed:27849005
pubmed:28646158
pubmed:28772281
pubmed:29476383
pubmed:30139840
pubmed:31042587
pubmed:31433065
pubmed:31792037
pubmed:31897526
pubmed:33105604
pubmed:33322337
pubmed:33509009
pubmed:34071893
pubmed:34110249
pubmed:34982265
pubmed:36048501
pubmed:36415951
pubmed:37094617
pubmed:37435490
pubmed:37725888
pubmed:37810891
wikipedia.en:Linsitinib

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from linsitinib

Phenotype where environments contain linsitinib

Phenotype modified by environments containing linsitinib

Phenotype affecting linsitinib

Human Disease Model